Drugs / Phleum pratense pollen extract
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01489033 | Jan → Apr 2010 | allergic disease | Roxall Medicina España S.A | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04603456 | Sep 2018 → Mar 2019 | allergic rhinitis | Zagazig University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phleum pratense pollen extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01489033 ↗ |
| Known as | Standardized Timothy Grass Pollen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04603456 ↗ |
| Route | Subcutaneous | “Subcutaneous immunotherapy with Phleum pratense pollen extract” NCT01489033 ↗ |